Medac resubmits treosulfan NDA to FDA, says Medexus Pharmaceuticals

By on    Pharma Industry News  

Medac resubmits treosulfan NDA to FDA, says Medexus Pharmaceuticals

Medexus Pharmaceuticals said that its strategic partner medac has resubmitted the new drug application (NDA) for treosulfan with the US Food and Drug Administration (FDA). Treosulfan is part of a preparative regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT). It is intended to be used in combination with fludarabine for the treatment of eligible patients […]

Race Oncology doses first patient in phase 1b/2 AML trial of FluCloZan

By on    Pharma Industry News  

Race Oncology doses first patient in phase 1b/2 AML trial of FluCloZan

Race Oncology has dosed the first patient in the phase 1b/2 trial of its Zantrene (bisantrene dihydrochloride) in combination with Fludarabine and Clofarabine (FluCloZan) in relapsed/refractory acute myeloid leukaemia (AML). According to the Australian precision oncology company, the early-stage clinical trial will study the FluCloZan regimen as salvage therapy to be administered intravenously in adult […]